Article
Biochemistry & Molecular Biology
Jisu Jeong, Jiyeon Kim
Summary: EMT plays a crucial role in the development of lung cancer, and targeting EMT could inhibit cancer cell invasion and metastasis. This study found that combination treatment with erlotinib and cilengitide showed enhanced inhibitory effects on EMT in lung cancer cells, suggesting that cilengitide could improve the efficacy of anticancer drugs and contribute to improved treatment strategies for inhibiting EMT-based cancer progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Przemyslaw Bieganski, Martina Godel, Chiara Riganti, Daniel Fabio Kawano, Joanna Kopecka, Konrad Kowalski
Summary: A library of 1,4- and 1,5-triazole ferrocenyl derivatives of erlotinib were synthesized and their anticancer activity was studied against erlotinib-sensitive and erlotinib-resistant lung cancer cells. Among the compounds investigated, two isomers showed superior activity against erlotinib-resistant cells, with a mechanism of action different from erlotinib.
BIOORGANIC CHEMISTRY
(2022)
Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
Summary: Treatment resistance to targeted agents is a significant challenge in cancer therapy and is also observed in EGFR-mutant NSCLC. Current efforts focus on delaying or overcoming acquired resistance, and targeting compensatory feedback loops along with oncogenic signaling pathways holds promise for improved outcomes.
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Osterborg, Hakan Mellstedt, Mohammad Hojjat-Farsangi
Summary: This study evaluated the expression of ROR1 in NSCLC patients and the cytotoxic effects of a small molecule ROR1 inhibitor in NSCLC cell lines. ROR1 was overexpressed in non-squamous and squamous carcinomas, as well as neuroendocrine tumors. The ROR1 inhibitor dephosphorylated ROR1 and induced apoptosis, and also inhibited the proliferation and migration of NSCLC cells. The combination of the ROR1 inhibitor and EGFR inhibitor showed a synergistic apoptotic effect.
Article
Pharmacology & Pharmacy
A. S. Pal, M. Bains, A. Agredo, A. L. Kasinski
Summary: Lung cancer is a major cause of cancer-related deaths, and overcoming resistance to EGFR inhibitors is crucial in the treatment of non-small cell lung cancer. This study identifies the important role of microRNAs in driving resistance to EGFR inhibitors in non-small cell lung cancer cells.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Limei Wang, Haitang Yang, Patrick Dorn, Sabina Berezowska, Fabian Blank, Carlos Wotzkow, Thomas M. Marti, Ren-Wang Peng, Nathalie Harrer, Wolfgang Sommergruber, Gregor J. Kocher, Ralph A. Schmid, Sean R. R. Hall
Summary: The study found that in non-small cell lung cancer, there is immune suppression in the stroma driven by TGF beta 1. Combining blockade of PD-L1 and TGF beta 1 with ID01 inhibition may enhance anti-tumor immunity.
Article
Pharmacology & Pharmacy
Ebony Nottingham, Elizabeth Mazzio, Sunil Kumar Surapaneni, Shallu Kutlehria, Arindam Mondal, Ramesh Badisa, Stephen Safe, Arun K. Rishi, Mandip Singh
Summary: The study demonstrates that CDODA-Me can enhance the sensitivity of ERL-resistant NSCLC cells to ERL, leading to synergistic therapeutic effects through inhibition of mitosis and induction of oxidative stress.
JOURNAL OF PHARMACEUTICAL ANALYSIS
(2021)
Article
Medicine, Research & Experimental
Mengran Zhang, Hao Cai, Yue Du, Yuexuan Wang, Jianhua Gong, Jian Xu, Xiujun Liu
Summary: The combination of DBDx and gefitinib shows promising antitumor efficacy in human NSCLC, inhibiting tumor growth significantly by suppressing cell proliferation, inducing apoptosis, and downregulating molecules associated with the EGFR signaling pathway. Further translational studies are warranted to explore its potential as a therapeutic approach.
MOLECULAR PHARMACEUTICS
(2021)
Article
Oncology
Celal Alandag, Elif Merev, Feyyaz Ozdemir
Summary: This study investigated the effects of calcium channel blockers on erlotinib treatment for non-small cell lung cancer patients. The results showed that simultaneous use of calcium channel blockers and erlotinib improved overall survival and progression-free survival rates, indicating an additive effect for NSCLC. These findings may inspire future prospective studies in this area.
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Cong Xu, Ze-Bo Jiang, Le Shao, Zi-Ming Zhao, Xing-Xing Fan, Xinbing Sui, Li-Li Yu, Xuan-Run Wang, Ruo-Nan Zhang, Wen-Jun Wang, Ya-Jia Xie, Yi-Zhong Zhang, Xiao-Wen Nie, Chun Xie, Ju-Min Huang, Jing Wang, Jue Wang, Elaine Lai-Han Leung, Qi-Biao Wu
Summary: This study found that the combination of ll-elemene and erlotinib induced ferroptosis and enhanced the sensitivity to EGFR-TKIs in EGFR-TKI-resistant lung cancer patients.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Engineering, Biomedical
Duo Wang, Jun Zhou, Weimin Fang, Cuiqing Huang, Zerong Chen, Meng Fan, Ming-Rong Zhang, Zeyu Xiao, Kuan Hu, Liangping Luo
Summary: In this study, a multifunctional superparamagnetic nanotheranostic agent was developed to enhance the efficacy of Erlotinib in EGFR-wt NSCLC. The nanoparticles co-delivered Erlotinib and a VEGF inhibitor (Bev) to EGFR-wt tumors, inhibiting tumor growth and promoting vascular normalization. The tumor engagement of nanoparticles and vascular normalization could be tracked by MRI.
BIOACTIVE MATERIALS
(2022)
Article
Nanoscience & Nanotechnology
Mei Cong, Houjun Pang, Guangxing Xie, Feifei Li, Chunxiao Li, Hao Sun, Shaoyou Yang, Weidong Zhao
Summary: This study presents a self-assemble amphiphilic molecule-based nanoformulation of erlotinib as an effective nanodrug for cancer treatment. The nanodrug exhibits a high drug loading, well-defined structure, small size, and effective tumor accumulation and internalization. Compared to free erlotinib, the erlotinib nanodrug shows significantly better anticancer activity in vitro and in vivo, with good tolerability. This novel nanomedicine shows promise as a therapeutic candidate for cancer treatment and highlights the potential use of amphiphilic molecules for nanodrug preparation.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Multidisciplinary Sciences
Chia- Shen, Chi-Lu Chiang, Tsu-Hui Shiao, Yung-Hung Luo, Heng-Sheng Chao, Hsu-Ching Huang, Chao-Hua Chiu
Summary: Detection of driver gene mutations is crucial in advanced NSCLC. The cobas EGFR mutation test has limitations due to its primer design, while next-generation sequencing-based assay provides a higher mutation detection coverage. Comprehensive genomic profiling can identify EGFR mutations missed by the cobas test and offers significant benefits to patients with NSCLC.
SCIENTIFIC REPORTS
(2022)
Review
Endocrinology & Metabolism
Zhaoying Yang, Le Zhang, Stefano Serra, Calvin Law, Alice Wei, Tracy L. Stockley, Shereen Ezzat, Sylvia L. Asa
ENDOCRINE PATHOLOGY
(2016)
Article
Oncology
Le Zhang, Zhaoying Yang, Letizia Granieri, Adrian Pasculescu, Alessandro Datti, Sylvia L. Asa, Zheli Xu, Shereen Ezzat
Review
Biotechnology & Applied Microbiology
Le Zhang, Chenghua Zhang, Zhaoying Yang, Miao He, Lijuan Zhang, Shereen Ezzat, Xi Liang
ONCOTARGETS AND THERAPY
(2017)
Review
Biotechnology & Applied Microbiology
Mingyue Duan, Hua Xing, Keren Wang, Chunbo Niu, Chengwei Jiang, Lijuan Zhang, Shereen Ezzat, Le Zhang
ONCOTARGETS AND THERAPY
(2018)
Article
Surgery
Xin Qi, Keren Wang, Denghua Sun, Le Zhang
JOURNAL OF SURGICAL RESEARCH
(2020)
Review
Biotechnology & Applied Microbiology
Le Zhang, Yuechen Wang, Leichao Zhang, Hua Xing, Chunbo Niu, Qiong Yu, Lu Tang
ONCOTARGETS AND THERAPY
(2020)